Reihane Ziadlou, PhD的动态

Happy to share our study showing that extracellular vesicles and their miRNA content contribute to NSAID-exacerbated respiratory disease (N-ERD). N-ERD is a severe type 2 chronic inflammatory disease, characterized by nasal polyposis, asthma and intolerance to NSAIDs such as Aspirin. In this study, published in Allergy, Franziska Hartung, Pascal Haimerl and colleagues show that small vesicles found in the airways of N-ERD patients modulate macrophage activation, resulting in reduced immune functions that are important for clearance of bacterial or viral pathogens. Our study thus identifies a new role for extracellular vesicles in type 2 airway inflammation and may explain why N-ERD patients are susceptible to infection-induced exacerbations.

?? A mini-update on chronic rhinosinusitis ?? Authors: Sepideh Darougar, Masoumeh Hematyar, Pantea Bozorg Savoji Explor Asthma Allergy. 2024;2:473–484 ?? DOI: https://lnkd.in/gv99JBtY ?? Keywords: #Chronic rhinosinusitis, T #cells, #endotype, #phenotype, #nasal #polyposis This article belongs to the special issue "Update on Chronic RhinoSinusitis”. It has published 4 articles, welcome to read them at https://lnkd.in/gFaYr4YN

?? A mini-update on chronic rhinosinusitis ?? Authors: Sepideh Darougar, Masoumeh Hematyar, Pantea Bozorg Savoji Explor Asthma Allergy. 2024;2:473–484 ?? DOI: https://lnkd.in/gv99JBtY ?? Keywords: #Chronic rhinosinusitis, T #cells, #endotype, #phenotype, #nasal #polyposis This article belongs to the special issue "Update on Chronic RhinoSinusitis”. It has published 4 articles, welcome to read them at https://lnkd.in/gFaYr4YN

#immunology #cells #biology #medicine #medicalsciences https://lnkd.in/dKArr8jk Abstract Eosinophils are bone marrow-derived #granulocytes that are traditionally associated with type 2 immune responses, such as those that occur during parasite #infections and #allergy. Emerging evidence demonstrates the remarkable functional plasticity of this elusive cell type and its pleiotropic functions in diverse settings. Eosinophils broadly contribute to tissue #homeostasis, host defence and immune regulation, predominantly at mucosal sites. The scope of their activities primarily reflects the breadth of their portfolio of secreted mediators, which range from cytotoxic cationic proteins and reactive oxygen species to multiple cytokines, chemokines and lipid mediators. Here, we comprehensively review basic eosinophil biology that is directly related to their activities in homeostasis, protective immunity, regeneration and cancer. We examine how dysregulation of these functions contributes to the physiopathology of a broad range of inflammatory diseases. Furthermore, we discuss recent findings regarding the tissue compartmentalization and adaptation of #eosinophils, shedding light on the factors that likely drive their functional diversification within tissues.

Very proud of this month’s issue and cover. The #skin is the largest immune organ, acting as a protective layer between the body and the environment. It restricts water loss and prevents the entering of harmful substances to deeper tissues. When environmental pollutants, parasites, and bacteria compromise the skin barrier, alarmins are produced, initiating type 2 immune responses. Microbial dysbiosis of the skin has been observed in atopic dermatitis patients, characterized by a loss of microbial diversity and an overabundance of pathogenic Staphylococcus aureus. This microbial imbalance stimulates the production of inflammatory cells, such as T cells, dendritic cells, and macrophages, contributing to disease severity, and perpetuating inflammation, itching, and further disruption of the skin barrier. In this issue, Wang et al., in their comprehensive review, highlight the impact of climatic hazards linked to greenhouse gas emissions and atopic dermatitis. Tham et al. review the skin microbiome in pediatric atopic dermatitis and food allergy. Canani et al. provide an overview of the epithelial barriers of the skin, digestive tract, and airways, and explore how barrier dysfunction affects the course of allergic and inflammatory conditions. Müller and Maintz et al., in their review of treatments for atopic dermatitis, provide an update on recently approved biologics and oral Janus kinase (JAK) inhibitors. Del Duca and Dahabreh et al. evaluate transcriptomics of skin tape-strips in children with allergic asthma and uncover epidermal barrier dysfunction and biomarker abnormalities. Ruchti et al., using a mouse model, demonstrate that epidermal barrier impairment predisposes to excessive growth of Malassezia on the skin. Fritz et al. reveal key differences between tape-strips and biopsies in the identification of gene-expression changes in atopic dermatitis. Guttman-Yassky et al. provide evidence that IL-13 targeting with tralokinumab normalizes type 2 inflammation in atopic dermatitis. Rademacher et al. present a novel role of RNase inhibitor as a trigger factor of inflammation in atopic dermatitis by blocking the ribonuclease and antimicrobial activity of RNase 7, thereby enhancing the growth of Staphylococcus aureus. Jin and Lee et al. describe a novel Th2-proming subset of dendritic cells, particularly prevalent in severe atopic dermatitis. M. Kim, J. Kim, Kang, Heo, and Kang et al. evalute the efficacy and safety of topical Streptococcus postbiotic emollient in atopic dermatitis. Aoyama, Nakagawa, and Ichikawa et al. study the skin dysbiosis in atopic dermatitis from the neonatal stage to infancy. Craig et a. use a naturally occurring canine model of atopic dermatitis to examine IL-31 transcription in the skin over the course of an acute allergic flare and following….. The cover image depicts the colony Staphylococcus aureus. Photo credit: ? M Oeggerli 2007, supported by Pathology, Univ. Hosp. Basel and School of Life Sciences, FHNW, Muttenz.

?????????????????????????? ?????????? ?????????????? ?????? ?????????????? ??????????????????: ?????????? ?? ?????????????? ?????????????????? ?????????? ???????? ???????????? Rilzabrutinib shows significant improvement in itch, hives, and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), inadequately controlled by H1 antihistamines. These findings were presented at the 2024 AAAAI Annual Meeting, forming the basis for Phase 3 trials starting in 2024. Professor Marcus Maurer, M.D. Marcus Maurer Professor of Dermatology and Allergy, Executive Director of the Institute of Allergology at the Charité Berlin "People with CSU are living with debilitating symptoms such as intensely itchy recurrent hives, swelling, or both which can have a high impact on their day-to-day lives. These data are promising news for patients that cannot be controlled with standard-of-care antihistamines – the possibility of controlling itch rapidly with an oral medicine would offer an important advancement in the treatment of this disease." Naimish Patel, M.D.Naimish Patel Head of Global Development, Immunology and Inflammation, Sanofi Sanofi “These data reinforce the potential of rilzabrutinib as a treatment option for patients with moderate-to-severe CSU and we believe that the rapid improvement of itch could make a meaningful difference in alleviating the physical and psychosocial burden these patients suffer from. Based on these data, later this year we will advance rilzabrutinib into Phase 3 development in both CSU and prurigo nodularis, another skin disorder characterized by relentless itching. We also look forward to data readouts for rilzabrutinib in 2024 with the opportunity to further demonstrate its potential impact across multiple immune-mediated diseases." Key Results: Rilzabrutinib at 400 mg TID demonstrated significant reduction in weekly itch severity score (ISS7) at Week 12 [LSM -9.58 vs -6.31; p=0.0181], with notable improvements seen as early as Week 1. Significant reductions were also observed in weekly urticaria activity score (UAS7) [LSM -17.95 vs -11.20; p=0.0116] and weekly hives severity score (HSS7) [LSM -8.31 vs -4.89; p<0.0100]. Rilzabrutinib was well-tolerated with no events of cytopenia, bleeding, or atrial fibrillation. Common treatment-emergent adverse events included diarrhea (29.3% TID/BID, 7.9% QPM, 15% placebo), nausea (19.5% TID, 17.1% BID, 13.2% QPM, 5.0% placebo), headache (9.8% TID, 14.6% BID, 5.3% QPM), and abdominal pain (12.2% BID, 2.6% QPM, 5.0% placebo). Rilzabrutinib shows promise as a treatment option for CSU and prurigo nodularis. Phase 3 development is anticipated later in 2024, with ongoing investigations across multiple immune-mediated diseases. #ChronicUrticaria #Rilzabrutinib #CSU #AAAAI2024 #Immunology #SkinHealth #Phase2Results #ItchRelief #Dermatology

Cutaneous Immunology Market Size, Share, Trends & Competitive Analysis Global Report 2024-2032 Cutaneous immunology studies the immune system's role in skin health and disease. It explores how the skin's immune cells defend against pathogens, repair injuries, and regulate inflammation. This field also examines how dysregulation in skin immunity can lead to conditions like psoriasis, eczema, and skin allergies. Read Full Report@ https://lnkd.in/dN2tt5FV The advancements in medical research and increasing awareness of skin-related immune disorders. The rise in autoimmune skin conditions, such as psoriasis and eczema, has led to a greater demand for effective treatments. Additionally, innovations in biologic drugs and targeted therapies are driving the market forward. These developments offer more precise and effective treatment options, improving patient outcomes and expanding the market's potential. #CutaneousImmunology #SkinImmunity #DermatologyResearch #SkinDiseases #ImmuneSystem #SkinHealth #ResearchInDermatology

?? Publication alert: ESCD position paper on patch testing ?? Patch testing is the only clinically applicable diagnostic method for Type IV allergy. The availability of Type IV patch test (PT) allergens in Europe, however, is currently scarce. This severely compromises adequate diagnostics of contact allergy, leading to serious consequences for the affected patients. ? Against this background, the European Society of Contact Dermatitis (ESCD) has created a task force (TF) (i) to explore the current availability of PT substances in different member states, (ii) to highlight some of the unique characteristics of Type IV vs. other allergens and (iii) to suggest ways forward to promote and ensure availability of high-quality patch testing substances for the diagnosis of Type IV allergies throughout Europe. ? The suggestions of the TF on how to improve the availability of PT allergens are supported by the ESCD, the European Academy of Allergy and Clinical Immunology, and the European Academy of Dermatology and Venereology and intend to provide potential means to resolve the present medical crisis. Full text available at (open access): https://lnkd.in/dgR5mGZd #science #allergy #dermatitis #dermatology

#dr_khalid_zohair Corneal neovascularization (CNV) is the in-growth of new blood vessels from the pericorneal plexus into avascular corneal tissue as a result of oxygen deprivation. Maintaining avascularity of the corneal stroma is an important aspect of healthy corneal physiology as it is required for corneal transparency and optimal vision. A decrease in corneal transparency causes visual acuity deterioration. It is a nonspecific response to different clinical insults, rather than a diagnosis, develops in a wide variety of corneal pathologies including congenital diseases, contact lens-related hypoxia, inflammatory disorders, chemical burns, limbal stem cell deficiency, allergy, trauma, infectious keratitis, autoimmune diseases, and corneal graft rejection. don't forget to mention this data were collected and published by dr khalid zohair, These pathologies lead to a disequilibrium between proangiogenic and antiangiogenic factors that can result in the proliferation and migration of vascular endothelial cells into the corneal stroma.variety of off-lab treatment approaches, such as topical treatments, anti-VEGF injections and laser/ phototherapy, have been shown to produce varying degrees of effectiveness, The main therapeutic aim of these treatments is to initiate anti-angiogenesis and inhibit the neoangiogenesis at early stages, whereas the other treatment modality aims to achieve angio-regression by inducing reversion of immature vessels.

The American Academy of Allergy, Asthma and Immunology - AAAAI and the American College of Allergy, Asthma and Immunology (ACAAI) Joint Task Force recently released updated guidelines for AD management, encompassing several of the latest medications and addressing five crucial questions related to AD management: 1. Among patients with AD, what topical treatments should be used to achieve optimal outcomes? 2. Should elimination diets (dietary avoidance strategies) be used for AD? 3. Should dilute bleach baths be used for AD? 4. Should allergen immunotherapy be used for AD? 5. Among patients with AD, what systemic treatments, including phototherapy (UV light therapy), should be used to achieve optimal outcomes? In this article, we provide an overview of essential discoveries and delve into the practical consequences in a clinical context. https://lnkd.in/dDbh_wrX Peter Lio, MD Gabrielle Osher Derek Chu, MD, PhD